Pepgen
Oxford
About Pepgen
PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides, and they are advancing novel conjugate therapeutics to the clinic.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $354.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:PEPG
- Website: pepgen.com
- Phone: +44 1865 618 820
Industries & Categories
Biotechnology, Clinical Trials, Medical
Social Profiles
Canonical: https://fsome.com/organization/pepgen-46914 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.